Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dennis Delpaine

Allergy & Immunology Stockton, CA Medical Doctor

NPI 1851452213 CMS profile 356110

5309 Carrington Circle, Stockton, CA 95210

Open in the dashboard

General payments

$12,684

635 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Delpaine of Stockton, CA is reported in the CMS Open Payments database as having received $12,684 across 635 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,419 75
2024 General $2,351 116
2023 General $2,213 107
2022 General $1,752 83
2021 General $1,584 80
2020 General $1,479 77
2019 General $1,886 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Delpaine
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Dennis Delpaine were reported at $1,419. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Dennis Delpaine Allergy & Immunology median Middle half National median
2019 $1,886 $594 $163–$1,512 $163
2020 $1,479 $426 $106–$1,233 $114
2021 $1,584 $638 $157–$1,708 $132
2022 $1,752 $790 $205–$1,961 $149
2023 $2,213 $852 $220–$2,147 $160
2024 $2,351 $865 $203–$2,267 $164
2025 $1,419 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,299 155 payments
  2. AbbVie, Inc. $1,637 111 payments
  3. Novartis Pharmaceuticals Corporation $1,577 72 payments
  4. GlaxoSmithKline, LLC. $899 58 payments
  5. Genzyme Corporation $764 25 payments
  6. Janssen Biotech, Inc. $753 31 payments
  7. Pfizer Inc. $563 24 payments
  8. Genentech USA, Inc. $444 20 payments
  9. AstraZeneca Pharmaceuticals LP $405 8 payments
  10. Sanofi-Aventis U.S. LLC $395 6 payments
  11. Other $2,950 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,400 629 payments
  2. Education $284 6 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,262 84 payments
  2. COSENTYX Immunology $987 52 payments
  3. TREMFYA $690 28 payments
  4. COSENTYX Dermatology $572 18 payments
  5. Enbrel $499 32 payments
  6. Actemra $481 20 payments
  7. BENLYSTA $449 18 payments
  8. XELJANZ $448 18 payments
  9. Otezla $442 27 payments
  10. DUPIXENT $421 21 payments
  11. Other $7,972 402 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

5,414

Median for Rheumatology: 1,511

Drug cost

$2,081,166

Median for Rheumatology: $1,139,948

Branded share of claims

30.4%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 63 $627,886
Enbrel Etanercept Brand 45 $356,191
Enbrel Sureclick Etanercept Brand 31 $281,561
Humira(Cf) Adalimumab Brand 15 $279,092
Rinvoq Upadacitinib Brand 16 $102,824
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $86,041
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $65,771
Nucala Mepolizumab Brand 12 $45,496
Hydroxychloroquine Sulfate Generic 1,016 $43,293
Teriparatide Generic 14 $32,551

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$607,722

Of which drugs: $431,926

Medicare patients

491

Average age 74

Services billed

56,602

341 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Chronic kidney disease 24%
Ischemic heart disease 23%
Osteoporosis 20%
Depression 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg Q5104 Office 17 2,100 $47,984
Injection, denosumab, 1 mg J0897 Office 26 2,280 $44,861
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg Q5121 Office 11 500 $9,205

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$286 16 —
TREMFYA
$237 — —
COSENTYX
$218 12 —
DUPIXENT
$215 — —
Enbrel
$156 76 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

635 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record